Latest Breaking News On - Progressive multifocal - Page 1 : comparemela.com

FDA Okays First Biosimilar for Multiple Sclerosis

Sandoz s natalizumab-sztn injection (Tyruko) is on par with Biogen s Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.

Paulr leeDrug administrationDivision of neurologyDrug evaluationMedscape medical newsEastern europeanExpanded disability status scaleMultiple sclerosis msMultiple sclerosisRelapsing remitting multiple sclerosisUltiple sclerosis relapsing remittingBiosimilar drugsFollow on biologicsSecondary progressive multiple sclerosisBiologic therapyUs food and drug administration

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

/PRNewswire/ Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a clinical stage development and commercialization platform company focused on cell.

Cellevolve bioDerrell porterDrug administrationPrnewswire cellevolve bio incCompany or cellevolveInvestigational new drugSpecifict cell therapyProgressive multifocalRankin scoreBanking amp financial servicesHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesFda approval

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cellevolve bioDerrell porterDrug administrationPrnewswire cellevolve bio incCompany or cellevolveInvestigational new drugSpecifict cell therapyProgressive multifocalRankin score

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

/PRNewswire/ Cellevolve Bio, Inc. ("the Company" or "Cellevolve"), a development and commercialization platform company focused on cell therapies, today.

Rajiv khannaCellevolve bioIrene corteseDerrell porterBerghofer medical research institute professor rajiv khannaNational institutes of healthDrug administrationPrnewswire cellevolve bio incCompany or cellevolveNational institute of neurological disordersMedical research instituteProfessor rajiv khannaLead primary investigatorSpecifict cell therapyRankin scoreNational institute

IPO Alert: Inhibikase Therapeutics (IKT)

IPO Alert: Inhibikase Therapeutics (IKT) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol IKT. Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinson s disease and related disorders. The company has offered to sell 1.8 million shares of its common stock at a price of $10 each. The underwriters have an option for a period of 45 days to purchase up to an additional 270 thousand shares. The offering, which is scheduled to close on December 28, is expected to fetch gross proceeds of about $18 million for the company.

Bruxelles capitaleKostenloser wertpapierhandelPaulson investment companyFordham financial management incNasdaq global select marketGeorgia based inhibikase therapeuticsFordham financial managementChronic myelogenousLewy bodyMultiple system atrophyProgressive multifocalப்ரூக்ஸெல்ஸ் தலைநகரம்பால்சன் முதலீடு நிறுவனம்ஃபார்டம் நிதி மேலாண்மை இன்க்நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தைஃபார்டம் நிதி மேலாண்மை